Liver Cancer Diagnostics Market - 2024-2031
Liver Cancer Diagnostics Marketis is growing with a CAGR of 6.60% during the forecast period 2026-2035.
The Liver Cancer Diagnostics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Liver Cancer Diagnostics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Test Type
Both primary and secondary data sources have been used in the global Liver Cancer Diagnostics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Liver Cancer Diagnostics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Liver Cancer Diagnostics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Test Type
- Alpha-fetoprotein (AFP) tumor marker test*
- Laboratory Tests
- Biomarker
- Oncofetal and Glycoprotein Antigens
- Enzymes and Isoenzymes
- Growth Factors and Receptors
- Molecular Markers
- Pathological Biomarkers
- Blood Tests
- Liver function tests (LFTs)
- Blood clotting tests
- Kidney function tests
- Complete blood count (CBC)
- Blood chemistry tests and other tests
- Biopsy
- Fine-needle aspiration biopsy
- Core needle biopsy
- Laparoscopy
- Imaging
- Ultrasound
- Computed tomography (CT)
- Magnetic resonance imaging (MRI)
- Angiography
- Others
- Others
- Hospitals*
- Cancer Research Institutes
- Diagnostic Laboratories
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Liver Cancer Diagnostics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Test Type
3.2. Snippet by End User
3.3. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Clinical Trials by the Market Players for the Early Detection of Liver Cancer
4.1.1.2. Development of New Biomarkers for the Early Detection of Liver Cancer
4.1.2. Restraints
4.1.2.1. The High Cost of Liver Cancer Screening
4.1.3. Opportunity
4.1.3.1. Rising Demand for Point-Of-Care Testing (POCT) in Liver Cancer Diagnostics
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. BY TEST TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.1.2. Market Attractiveness Index, By Test Type
8.2. Alpha-fetoprotein (AFP) tumor marker test*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Laboratory Tests
8.3.1. Biomarker
8.3.1.1. Oncofetal and Glycoprotein Antigens
8.3.1.2. Enzymes and Isoenzymes
8.3.1.3. Growth Factors and Receptors
8.3.1.4. Molecular Markers
8.3.1.5. Pathological Biomarkers
8.3.2. Blood Tests
8.3.2.1. Liver function tests (LFTs)
8.3.2.2. Blood clotting tests
8.3.2.3. Kidney function tests
8.3.2.4. Complete blood count (CBC)
8.3.2.5. Blood chemistry tests and other tests
8.4. Biopsy
8.4.1. Fine-needle aspiration biopsy
8.4.2. Core needle biopsy
8.4.3. Laparoscopy
8.5. Imaging
8.5.1. Ultrasound
8.5.2. Computed tomography (CT)
8.5.3. Magnetic resonance imaging (MRI)
8.5.4. Angiography
8.5.5. Others
8.6. Others
9. BY END USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cancer Research Institutes
9.4. Diagnostic Laboratories
9.5. Others
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.5.1. U.S.
10.2.5.2. Canada
10.2.5.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.5.1. Germany
10.3.5.2. U.K.
10.3.5.3. France
10.3.5.4. Italy
10.3.5.5. Spain
10.3.5.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.5.1. Brazil
10.4.5.2. Argentina
10.4.5.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. COMPETITIVE LANDSCAPE
11.1. Competitive Scenario
11.2. Product Benchmarking
11.3. Company Share Analysis
11.4. Key Developments and Strategies
12. COMPANY PROFILES
12.1. Abbott Laboratories*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. F. Hoffmann-La Roche Ltd.
12.3. Qiagen N.V.
12.4. Thermo Fisher Scientific, Inc.
12.5. Siemens Healthineers
12.6. BD
12.7. Illumina, Inc.
12.8. Koninklijke Philips N.V
12.9. Epigenomics AG
12.10. Fujifilm Medical Systems U.S.A., Inc.
12.11. Sysmex Corporation(*LIST NOT EXHAUSTIVE)
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Test Type
3.2. Snippet by End User
3.3. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Clinical Trials by the Market Players for the Early Detection of Liver Cancer
4.1.1.2. Development of New Biomarkers for the Early Detection of Liver Cancer
4.1.2. Restraints
4.1.2.1. The High Cost of Liver Cancer Screening
4.1.3. Opportunity
4.1.3.1. Rising Demand for Point-Of-Care Testing (POCT) in Liver Cancer Diagnostics
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. BY TEST TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.1.2. Market Attractiveness Index, By Test Type
8.2. Alpha-fetoprotein (AFP) tumor marker test*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Laboratory Tests
8.3.1. Biomarker
8.3.1.1. Oncofetal and Glycoprotein Antigens
8.3.1.2. Enzymes and Isoenzymes
8.3.1.3. Growth Factors and Receptors
8.3.1.4. Molecular Markers
8.3.1.5. Pathological Biomarkers
8.3.2. Blood Tests
8.3.2.1. Liver function tests (LFTs)
8.3.2.2. Blood clotting tests
8.3.2.3. Kidney function tests
8.3.2.4. Complete blood count (CBC)
8.3.2.5. Blood chemistry tests and other tests
8.4. Biopsy
8.4.1. Fine-needle aspiration biopsy
8.4.2. Core needle biopsy
8.4.3. Laparoscopy
8.5. Imaging
8.5.1. Ultrasound
8.5.2. Computed tomography (CT)
8.5.3. Magnetic resonance imaging (MRI)
8.5.4. Angiography
8.5.5. Others
8.6. Others
9. BY END USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cancer Research Institutes
9.4. Diagnostic Laboratories
9.5. Others
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.5.1. U.S.
10.2.5.2. Canada
10.2.5.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.5.1. Germany
10.3.5.2. U.K.
10.3.5.3. France
10.3.5.4. Italy
10.3.5.5. Spain
10.3.5.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.5.1. Brazil
10.4.5.2. Argentina
10.4.5.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. COMPETITIVE LANDSCAPE
11.1. Competitive Scenario
11.2. Product Benchmarking
11.3. Company Share Analysis
11.4. Key Developments and Strategies
12. COMPANY PROFILES
12.1. Abbott Laboratories*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. F. Hoffmann-La Roche Ltd.
12.3. Qiagen N.V.
12.4. Thermo Fisher Scientific, Inc.
12.5. Siemens Healthineers
12.6. BD
12.7. Illumina, Inc.
12.8. Koninklijke Philips N.V
12.9. Epigenomics AG
12.10. Fujifilm Medical Systems U.S.A., Inc.
12.11. Sysmex Corporation(*LIST NOT EXHAUSTIVE)
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
